This is a preview of subscription content, log in via an institution to check access.
References
Wu JJ, et al. A Cost-Effectiveness Analysis of Commonly Used Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS8, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80258?pdfid=54943.
Xue W, et al. Cost-Effectiveness Analysis of Brodalumab in Moderate-to-Severe Plaque Psoriasis in Canada. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS12, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/81456?pdfid=54964.
Feldman SR, et al. The Budget Impact of Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis on U.S. Commercial Health Plans. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS6, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80262?pdfid=54944.
Rights and permissions
About this article
Cite this article
Brodalumab good choice in psoriasis. PharmacoEcon Outcomes News 805, 9 (2018). https://doi.org/10.1007/s40274-018-5011-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5011-2